Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity
Huleatt JW, Jacobs AR, Tang J, Desai P, Kopp EB, Huang Y, Song L, Nakaar V, Powell TJ. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 2006, 25: 763-775. PMID: 16968658, DOI: 10.1016/j.vaccine.2006.08.013.Peer-Reviewed Original ResearchConceptsCD8 T cell responsesT cell responsesAntigen-specific responsesCell responsesRecombinant fusion proteinAntigen fusion proteinProtective CD8 T cell responsesAntigen-specific CD8 T-cell responsesPotent antigen-specific responsesToll-like receptor ligandsToll-like receptor (TLR) familyComplete Freund's adjuvantDay of immunizationB cell responsesTLR5 ligand flagellinImmunization of miceRecombinant protein vaccineVirulent L. monocytogenesSupplemental adjuvantsProtective immunityTLR ligandsFreund's adjuvantHumoral immunityProtein vaccineEnhanced immunogenicity